直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 116474
タイトル別表記
Analysis of DOC and Ram for NSCLC
著者
Yoshimura, Akihiro Kyoto Prefectural University of Medicine
Yamada, Tadaaki Kyoto Prefectural University of Medicine
Okuma, Yusuke Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Kitadai, Rui Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Takeda, Takayuki Uji-Tokushukai Medical Center
Kanematsu, Takanori Matsuyama Red Cross Hospital
Harada, Taishi Fukuchiyama City Hospital
Kubota, Yutaka Japanese Red Cross Kyoto Daini Hospital
Yamada, Takahiro Matsushita Memorial Hospital
Date, Koji Kyoto Chubu Medical Center
Shiotsu, Shinsuke Japanese Red Cross Kyoto Daiichi Hospital
Nagata, Kazuhiro Koseikai Takeda Hospital
Chihara, Yusuke Kyoto Prefectural University of Medicine
Kaneko, Yoshiko Kyoto Prefectural University of Medicine
Uchino, Junji Kyoto Prefectural University of Medicine
Takayama, Koichi Kyoto Prefectural University of Medicine
キーワード
Docetaxel (Doc)
ramucirumab (Ram)
programmed death-ligand 1
non-small cell lung cancer (NSCLC)
retrospective study
資料タイプ
学術雑誌論文
抄録
Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram.
Methods: We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018.
Results: Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041).
Conclusions: Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients.
掲載誌名
Translational Lung Cancer Research
ISSN
22186751
22264477
出版者
AME Publishing Company
8
4
開始ページ
450
終了ページ
460
発行日
2019-08
権利情報
This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/)
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系
病院